Physician profile
Hailey Newberry
NPI 1699465930
$10,712.50
in general payments reported to CMS, 2019-2025
20 companies · $4,030 in 2025
The $4,030 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,882 · 2024: $4,800 · 2025: $4,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,267.26 |
| Education | $445.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,481.36 | 2023-2025 | |
| Incyte Corporation | $1,061.04 | 2023-2025 | Opzelura, Opzelura, Iclusig |
| Janssen Biotech, INC. | $1,031.02 | 2023-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $883.56 | 2023-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $760.49 | 2023-2025 | Dupixent |
| Genzyme Corporation | $727.25 | 2023-2025 | |
| Ucb, INC. | $710.66 | 2024-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $549.26 | 2023-2025 | Winlevi, Blu-U |
| Arcutis Biotherapeutics, INC. | $473.55 | 2024-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $381.13 | 2023-2025 | |
| Galderma Laboratories, L.P. | $347.20 | 2024-2025 | Nemluvio, Aklief |
| Lilly USA, LLC | $341.17 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $313.50 | 2024-2025 | Otezla, Otezla |
| Leo Pharma INC. | $171.68 | 2025 | Adbry, Anzupgo, Spevigo |
| Pfizer INC. | $125.00 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $120.14 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $100.51 | 2024-2025 | Cabtreo, Jublia, Siliq |
| Janssen Scientific Affairs, LLC | $85.33 | 2024 | Tremfya |
| Biofrontera INC. | $25.73 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Almirall LLC | $22.92 | 2024 | Seysara |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hailey Newberry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.